Effects of Various Concentrations of Pronase on Flow Cytometric Crossmatching Patients Treated With Rituximab and Donor HLA-Specific Antibodies
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Pronase pretreatment can reduce rituximab (RTX) interference by degrading CD20 in B-cell flow cytometry crossmatch (FCXM) testing. However, it may also reduce the assay sensitivity by degrading HLA molecules. We investigated the effects of various pronase concentrations on RTX interference and the analytical sensitivity of B-cell FCXM testing. Methods: Using 59 patient serum samples and 38 donor lymphocyte samples, we designed 97 recipient–donor pairs and divided them into three groups according to RTX use and the presence of weak-to-moderate donor HLA-specific antibody (DSA) reactions: RTX+/ DSA−, RTX+/DSA+, and RTX−/DSA+. FCXM was performed after pretreating lymphocytes with six different pronase concentrations (0, 0.5, 1, 2, 3, and 4 mg/mL). Results: With B-FCXM testing, false-positive results due to RTX in the RTX+/DSA– group markedly decreased with increasing pronase concentrations. The median channel shift values in the RTX+/DSA+ and RTX−/DSA+ groups did not significantly decrease when the pronase concentration was increased from 1 mg/mL to 2 or 3 mg/mL. All eight RTX+/ DSA+ cases that were positive at 1 mg/mL pronase but negative at 2 or 3 mg/mL had mean fluorescence intensity (MFI) DSA values of less than 3,000 except for DQ5 (MFI: 5,226). With T-cell FCXM, false-positive results were observed in 2.9% of 315 FCXM tests with pronase pretreatment. Conclusions: Higher concentrations (2 or 3 mg/mL) of pronase effectively eliminated RTX interference but still carried a risk for false negativity for weak DSA reactions in B-cell FCXM. Higher pronase concentrations can be used as an auxiliary method to detect moderate- to-strong DSA reactions in RTX-treated patients.
Abstract
Background: Pronase pretreatment can reduce rituximab (RTX) interference by degrading CD20 in B-cell flow cytometry crossmatch (FCXM) testing. However, it may also reduce the assay sensitivity by degrading HLA molecules. We investigated the effects of various pronase concentrations on RTX interference and the analytical sensitivity of B-cell FCXM testing. Methods: Using 59 patient serum samples and 38 donor lymphocyte samples, we designed 97 recipient–donor pairs and divided them into three groups according to RTX use and the presence of weak-to-moderate donor HLA-specific antibody (DSA) reactions: RTX+/ DSA−, RTX+/DSA+, and RTX−/DSA+. FCXM was performed after pretreating lymphocytes with six different pronase concentrations (0, 0.5, 1, 2, 3, and 4 mg/mL). Results: With B-FCXM testing, false-positive results due to RTX in the RTX+/DSA– group markedly decreased with increasing pronase concentrations. The median channel shift values in the RTX+/DSA+ and RTX−/DSA+ groups did not significantly decrease when the pronase concentration was increased from 1 mg/mL to 2 or 3 mg/mL. All eight RTX+/ DSA+ cases that were positive at 1 mg/mL pronase but negative at 2 or 3 mg/mL had mean fluorescence intensity (MFI) DSA values of less than 3,000 except for DQ5 (MFI: 5,226). With T-cell FCXM, false-positive results were observed in 2.9% of 315 FCXM tests with pronase pretreatment. Conclusions: Higher concentrations (2 or 3 mg/mL) of pronase effectively eliminated RTX interference but still carried a risk for false negativity for weak DSA reactions in B-cell FCXM. Higher pronase concentrations can be used as an auxiliary method to detect moderate- to-strong DSA reactions in RTX-treated patients.
참고문헌 (16)
- Abbes S, "Human leukocyte antigen sensitization in solid organ transplantation: a primer on terminology, testing, and clinical significance for the apheresis practitioner", Ther Apher Dial, 21, pp.441~450 (2017)
- Downing J, "The lymphocyte crossmatch by flow cytometry for kidney transplantation", Methods Mol Biol, 882, pp.379~390 (2012)
- Nam M, "Impact of low-level donor-specific antibody determined with a positive luminex and negative flow cytometric crossmatch on kidney transplantation outcomes", Ann Lab Med, 43, pp.325~327 (2023)
- Guillaume N, "Improved flow cytometry crossmatching in kidney transplantation", HLA, 92, pp.375~383 (2018)
- Lázár-Molnár E, "Implications of monoclonal antibody therapeutics use for clinical laboratory testing", Clin Chem, 65, pp.393~405 (2019)
- Kueht ML, "Antibody therapeutics as interfering agents in flow cytometry crossmatch for organ transplantation", J Pers Med, 13, pp.1005~ (2023)
- Bearden CM, "Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab", Hum Immunol, 65, pp.803~809 (2004)
- Lobo PI, "The use of pronase-digested human leukocytes to improve specificity of the flow cytometric crossmatch", Transpl Int, 8, pp.472~480 (1995)
- Vaidya S, "Improved flow cytometric detection of HLA alloantibodies using pronase : potential implications in renal transplantation", Transplantation, 71, pp.422~428 (2001)
- Apithy MJ, "Pronase treatment improves flow cytometry crossmatching results", HLA, 90, pp.157~164 (2017)
- Kang H, "Causes of positive pretransplant crossmatches in the absence of donor-specific anti-human leukocyte antigen antibodies : a single-center experience", Ann Lab Med, 41, pp.429~435 (2021)
- Park H, "Frequent false-positive reactions in pronase-treated T-cell flow cytometric cross-match tests", Transplant Proc, 44, pp.87~90 (2012)
- Hetrick SJ, "Impact of pronase on flow cytometric crossmatch outcome", Hum Immunol, 72, pp.330~336 (2011)
- Szewczyk K, "Flow cytometry crossmatch reactivity with pronase-treated T cells induced by non-HLA autoantibodies in human immunodeficiency virus-infected patients", Hum Immunol, 77, pp.449~455 (2016)
- Tait BD, "Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation", Transplantation, 95, pp.19~47 (2013)
- Silva C, "Low expression loci and the use of pronase in flow cytometry crossmatch", Transplant Proc, 55, pp.1383~1389 (2023)